# Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer

> **NCT01637805** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Stage IV Gastric Cancer

## Interventions

- **BIOLOGICAL:** Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene

## Key facts

- **NCT ID:** NCT01637805
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01637805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01637805, "Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01637805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*